C.R. Bard VP Unloads $337,500 in Stock (BCR)
C.R. Bard (NYSE:BCR) VP Sharon M. Luboff unloaded 2,500 shares of the stock on the open market in a transaction dated Monday, January 13th. The stock was sold at an average price of $135.00, for a total value of $337,500.00. Following the sale, the vice president now directly owns 42,381 shares of the company’s stock, valued at approximately $5,721,435. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
C.R. Bard (NYSE:BCR) traded up 0.44% during mid-day trading on Wednesday, hitting $136.00. The stock had a trading volume of 538,635 shares. C.R. Bard has a one year low of $97.14 and a one year high of $141.02. The stock has a 50-day moving average of $134.5 and a 200-day moving average of $123.8. The company has a market cap of $10.593 billion and a P/E ratio of 74.73.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $758.00 million for the quarter, compared to the consensus estimate of $739.12 million. During the same quarter in the prior year, the company posted $1.64 earnings per share. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Analysts expect that C.R. Bard will post $5.75 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, January 31st. Investors of record on Tuesday, January 21st will be given a dividend of 0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, January 16th.
A number of analysts have recently weighed in on BCR shares. Analysts at Barclays raised their price target on shares of C.R. Bard from $140.00 to $150.00 in a research note to investors on Thursday, January 9th. They now have an “overweight” rating on the stock. Separately, analysts at Atlantic Securities upgraded shares of C.R. Bard from a “neutral” rating to an “overweight” rating in a research note to investors on Wednesday, January 8th. They now have a $148.00 price target on the stock, up previously from $118.00. Finally, analysts at JPMorgan Chase & Co. downgraded shares of C.R. Bard from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, January 6th. They now have a $142.00 price target on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $131.31.
C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.